Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers
Hongsheng Deng, Hengrui Liang, Jiawei Chen, Wei Wang, Jianfu Li, Shan Xiong, Bo Cheng, Caichen Li, Zhuxing Chen, Haixuan Wang, Jianqi Zheng, Zhuoxuan Guo, Jianxing He, Wenhua Liang
Abstract
Background: This retrospective study aimed to evaluate the real-world efficacy of neoadjuvant immunochemotherapy in locally advanced stage III non-small cell lung cancer (NSCLC), with a particular focus on analyzing the optimal treatment cycle and peripheral immune markers. Methods: , 2021 were identified, and their oncological outcomes were collected. Results: 0.59, P=0.020) were significantly higher in MPR patients compared to non-MPR patients. Conclusions: The present study confirmed a favorable real-world tumor downstage efficacy of neoadjuvant immunochemotherapy in locally advanced NSCLC. Even though CR/PR was achieved, it is still beneficial when extended into 3-4 cycles of neoadjuvant immunochemotherapy.